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ABSTRACT 
 
Rationale: Chronic inflammation is central in the development of atherosclerosis. Both innate and adaptive 
immunity are involved. Although several studies have evaluated the functions of NK cells in experimental 
animal models of atherosclerosis, it is not yet clear whether NK cells behave as protective or pro-atherogenic 
effectors. One of the main caveats of previous studies was the lack of specificity in targeting loss- or gain-of-
function of NK cells. 
 
Objectives We used two selective genetic approaches to investigate the role of NK cells in atherosclerosis: 1) 
Ncr1iCre/+R26lsl-DTA/+ mice in which NK cells were depleted, 2) Noé mice in which NK cells are hyperresponsive. 
 
Methods and Results: No difference in atherosclerotic lesion size was found in Ldlr-/- mice transplanted with 
bone marrow cells from Ncr1iCreR26Rlsl-DTA, Noé or WT mice. Also, no difference was observed in plaque 
composition in terms of collagen content, macrophage infiltration or the immune profile, although Noé chimera 
had more IFN--producing NK cells, compared with WT mice. Then, we investigated the NK cell selectivity 
of anti-asialo GM1 anti-serum, which was previously used to conclude to the pro-atherogenicity of NK cells. 
Anti-asialo GM1 treatment decreased atherosclerosis in both Ldlr-/- mice transplanted with Ncr1iCreR26Rlsl-DTA 
or WT BM, indicating that its anti-atherogenic effects are unrelated to NK cell depletion, but to CD8+ T and 
NKT cells. Finally, to determine whether NK cells could contribute to the disease in conditions of pathological 
NK cell overactivation, we treated irradiated Ldlr-/- mice reconstituted with either WT or Ncr1iCreR26Rlsl-DTA BM 
with the viral mimic poly(I:C) and found a significant reduction of plaque size in NK-cell deficient chimeric 
mice. 
 
Conclusion: Our findings, using state-of-the-art mouse models, demonstrate that NK cells have no direct effect 
on the natural development of hypercholesterolemia-induced atherosclerosis, but may play a role when an 
additional systemic NK cell overactivation occurs. 
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asialo-GM1 asialoganglioside M1 
ATF2  activating transcription factor 2 
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Lsl  lox-stop-lox 
Ncr1  natural cytotoxicity triggering receptor 1 
NK  natural killer 
GFP  green fluorescent protein 
HFD  high-fat diet 
Ldlr-/-   low-density lipoprotein receptor-null 
poly(I:C) polyinosinic-polycytidylic acid 
TLR  Toll-like receptor 
WT  wild type 
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INTRODUCTION 
 
Atherosclerosis is a chronic inflammatory disease characterized by accumulation of cholesterol, 
immune cells, and fibrous elements, forming atherosclerotic plaques in large and medium sized arteries 1. Over 
the past 20 years, a large body of evidence supported the implication of innate and adaptive immunity in the 
development of the disease. Macrophages are the first immune cells to infiltrate developing lesions, as well as 
dendritic cells and T cells. However, less abundant cells such as NKT and NK cells are also present 2. NK cells 
are bone marrow (BM)-derived innate lymphocytes characterized by their unique ability to kill aberrant cells 
without prior sensitization 3. They act by means of direct cytotoxicity against their targets and by producing 
large array of cytokines and chemokines, the latter contributing also to the initiation of antigen-specific immune 
responses and thus shaping of adaptive immunity 4, 5. Regardless of their activation status and their localization 
NK cells express the NKp46 marker encoded by the Ncr1 gene. NK cells have been identified within 
atherosclerotic plaques in humans as well as in mice. In advanced atherosclerotic plaques, they have been 
localized to necrotic cores, deep within the plaques and in shoulder regions 6, 7. Chemoattractants such as CCL2 
and CX3CL1 may be involved in their recruitment to the developing lesions 8, 9. Directly addressing the role 
of NK cells in immunity and atherosclerosis has been challenging due to the lack of a good animal model of 
NK cell-deficiency. Earlier studies used the beige mutant mice, an accepted model of defective NK cell 
functional activity 10, with opposing results. In the first study, beige mutant mice fed a high fat diet (HFD) 
containing cholate showed no differences in atherosclerotic lesions compared to controls 11. However, in a more 
recent study by Schiller and his colleagues, NK cells were ascribed an athero-protective role when beige mutant 
mice were bred to Ldlr-/- mice 12. Beige mutation, which involves the Lyst gene encoding a protein implicated 
in lysosomal trafficking, results in a complicated phenotype that goes beyond decreased NK cell activity 13, 14. 
Defects in cell function may include, in addition to NK cells, neutrophils, macrophages, or smooth muscle cells 
(SMCs) 15, making it unclear whether the increase in atherosclerosis in LystbeigexLdlr-/- mice was a consequence 
of defective NK cell function.  
 
Subsequently, different results were observed using a Ly49A transgenic mouse model of NK cell 
deficiency 7. In these transgenic mice, the Ly49A cDNA was expressed under control of the mouse granzyme 
A genomic sequence, inducing the expression of the receptor on all NK cells and one-half of T cells 16. Ly49A 
is an inhibitory receptor, which recognizes MHC class-I molecules 17.  In this transgenic model, the number of 
NK (NK1.1+CD3−) cells was markedly reduced in the spleen and other peripheral tissues and the number of 
NK1.1+ T cells was slightly reduced in the spleen 16. However, this phenotype, which is not totally understood, 
is linked to the expression of the ubiquitous transcription factor ATF2, raising the possibility of additional 
defects 18. Smaller size lesions were observed in Ldlr-/- recipients reconstituted with the BM of ly49A transgenic 
mice 7. While the authors concluded that NK cell deficiency was responsible for the observed effect, they did 
not exclude the possibility that T cells, specifically NKT and CD8 subsets; which are known to express 
granzyme A and whose functions are influenced by Ly49A 19, 20 could contribute to this pro-atherogenicity. It 
is worth mentioning that NKT and CD8 T cells have been classified as proatherogenic cells 21 22. 
 
Lately, Selathurai et al. performed loss- and gain-of-function studies to assess NK cell function in 
atherosclerosis [22]. In the loss-of-function experiments, treatment of Apoe-/- mice with anti-asialo-GM-1 
antibody significantly reduced atherosclerotic lesion development. This study was supported by gain-of-
function experiments where adoptive transfer of NK cells (WT, IFN--/-, or perforin-/-/granzyme-/-) into 
lymphocyte-deficient Apoe-/- x Rag2-/- x Il2rg-/- mice confirmed that its cytotoxic effects are proatherogenic and 
promote necrotic core development 23. However, the glycolipid asialo-GM1 is also expressed by several cell 
types, including myeloid cells, epithelial cells, and T-cell subsets. Hence, the selectivity of NK cell depletion 
with anti-asialo-GM1 antiserum has been questioned 24. 
 
Here, we used two state-of-the-art genetic approaches: 1) The Ncr1iCreR26Rlsl-DTA mice in which NK 
cells are selectively depleted 25 2) The Noé mice in which NK cells are hyperresponsive 26. BM from these mice 
were used to re-populate the hematopoietic system of lethally irradiated Ldlr-/- mice fed a high fat diet (HFD). 
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Using these two genetic models, we provide strong evidence that NK cells do not significantly affect 
atherosclerosis development unless an additional inflammatory environment is induced. 
 
METHODS 
Animals. 
Experiments were conducted according to the guidelines formulated by the European Community for 
experimental animal use (L358-86/609EEC) and were approved by the Ethical Committee of INSERM and the 
French Ministry of Agriculture (agreement A75-15-32). Ncr1iCreR26Rlsl-DTA mice (deficient in NK cells) 25 and 
Noé mice (high IFN--producing- and CD107a-expressing- NK cells) 26 have been generated and characterized 
by Eric Vivier’s laboratory (CIML, Marseille, France).  
 
The Ncr1iCre KI mice 27 were bred to R26Rlsl-DTA mice to generate NK46iCre/+R26lsl-DTA/+ mice referred as to 
Ncr1iCreR26Rlsl-DTA mice thereafter. Ncr1iCre KI mice were generated from C57BL/6 ES cells and R26Rlsl-DTA mice 
were obtained from Jackson. This line was backcrossed to C57BL/6 for 10 generations by the donating 
laboratory 27. In this model, the Cre-mediated removal of the floxed STOP codon, leads to the expression of 
the diphtheria toxin fragment A and consequent cell death. A near to complete absence of NK cells in the bone 
marrow and every tested organ (including the blood, thymus, lymph nodes, spleen, liver) was observed in these 
mice 25. Of note, a deficiency in ILC1 (which also express NKp46) in the liver and in NKp46+ ILC3 in the small 
intestine was also observed in these mice. Aside from NKp46+ cell deficiency, the immune status of the mice 
is strictly normal at steady state, in terms of cell populations and activation status 25. 
 
The Noé mice were generated by random mutagenesis, in which a point mutation in the Ncr1 gene impairs the 
cell surface expression of NKp46 receptor inducing higher capacity to produce IFN- and to degranulate. Once 
generated, Noé mice were back-crossed to C57BL/6J 26. 
 
Ten-week-old male C57BL/6J Ldlr-/- mice were subjected to medullar aplasia by lethal total body irradiation 
(9.5 Gy). The mice were repopulated with an intravenous injection of BM cells isolated from femurs and tibias 
of sex-matched Ncr1iCreR26lsl-DTA, Noé, or control C57BL/6J mice. After four weeks of recovery, mice were fed 
a pro-atherogenic high fat diet (HFD) containing 15% fat, 1.25% cholesterol, and 0% cholate for 8, 12, or 15 
weeks.  
 
In some experiments, 14-week-old chimeric male Ldlr-/- mice, which received BM from Ncr1iCreR26lsl-DTA or 
control C57BL/6J mice, were treated every 5 days by intravenous injections of anti-asialo-GM-1 antibody (54 
µg/injection), Wako chemicals, Richmond, VA, USA) or control serum (normal rabbit serum) for 8 weeks 
HFD. We used the same experimental protocol as previously described by Selathurai et al 23. 
 
For NK cell-activation experiments, 14-week-old chimeric male Ldlr-/- mice, which received Ncr1iCre R26lsl-DTA 
or control C57BL/6J BM, were treated twice a week by intra-peritoneal injection of 100 µg polyinosinic-
polycytidylic acid [(poly(I:C)], a synthetic analogue of dsRNA, TLR3 ligand (Invivogen, SD, USA) or saline 
(as a control) during 8 weeks HFD. 
 
For tracking NK cells in mouse lesions, lethally irradiated Ldlr-/- mice were reconstituted with BM of Ncr-1gfp/gfp 
mice and put on HFD for 8 weeks. The generation of Ncr-1gfp/gfp mice was previously described by Gazit et al 
28. 
 
Quantification of atherosclerotic lesions. 
Mice were anesthetized with isoflurane before sacrifice. Plasma cholesterol was measured using a commercial 
kit (DiaSys® Cholesterol FS*, Germany). Quantification of lesion size and composition was performed as 
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previously described 29. Briefly, the heart and ascending aorta were removed, perfusion-fixed in situ with 4% 
paraformaldehyde, then placed in phosphate-buffered saline (PBS)-30% sucrose solution overnight, before 
being embedded in frozen optimal cutting temperature compound and frozen at -70°C. Afterwards, 10-m serial 
sections of aortic sinus were obtained (cut on cryostat). Lipids were detected using Oil Red O (Sigma-Aldrich, 
St. Louis, Missouri) coloration and quantified by a blinded operator using HistoLab software (Microvisions 
Instruments, Paris, France) 30, which was also used for morphometric studies. En face quantification was used 
for atherosclerotic plaques along thoraco-abdominal aorta, as previously described 29.  
 
Collagen was detected using Sirius red staining. The presence of macrophages was determined using 
monoclonal rat anti-mouse macrophage/monocyte antibody (MOMA)-2 (specifically MAB1852).  
 
At least 4 sections per mouse were examined for each immunostaining, and appropriate negative controls were 
used.  
 
For NK cell tracking, frozen sections of spleen and aortic sinus of Ncr-1gfp/gfp Ldlr-/- mice were stained with 
rabbit anti-GFP antibody (NK cells) and counterstained with DAPI (nuclear dye) and MOMA-2 antibody 
(monocytes/macrophages). 
 
To detect NK cells in human plaques, immunostaining studies were performed in atherosclerotic plaques from 
carotid arteries obtained after surgical thrombo-endaterectomy (Pathology department, HEGP hospital, Paris). 
We used a specific antibody against human NKp46 (generous gift of Innate Pharma, Marseille, France) in 
formalin fixed paraffin embedded tissues after antigen retrieval by heating in citrate buffer and ABC peroxidase 
technique as previously described 31. Spleen was used as an internal control in the two separate experiments. 
 
Spleen cell culture and cytokine assays. 
Cells were cultured in RPMI 1640 medium supplemented with Glutamax (Thermo Fischer Scientific), 10% 
fetal calf serum, 0.02 mM -mercapto-ethanol and antibiotics. For cytokine measurements, splenocytes were 
cultured at 5*105 cells/well for 24 hours and stimulated with lipopolysaccharide (LPS) (1 g/ml) and IFN- 
(100 UI/ml) (Sigma). IL-6, IL-12, TNF-, IL-1, IL-10, and IFN- productions in the supernatants were 
measured using specific ELISA (R&D Systems). 
 
Flow cytometry. 
NK cells were identified as CD3-NK1.1+ or CD3-NK1.1+NKp46+. Monocytes were identified as CD11b+Ly6G- 
or CD11b+CD115high. Among them, classical monocytes were Gr1high (or Ly6Chigh) and non-classical monocytes 
were Gr1low (or Ly6Clow). Neutrophils were identified as CD11b+CD115-Ly6G+. Regulatory T cells were 
considered as CD3+CD4+CD25highFoxp3+. CD4+, CD8+, and NKT (CD3+NK1.1+) lymphocyte subsets were also 
analyzed. 
 
Cells were labelled with FITC or PE-Cy7-conjugated anti-NKp46 (29A1.4), APC-conjugated anti-NK1.1 
(PK136), PerCp-Cy5.5-conjugated anti-CD3e (145-2C11), FITC-conjugated anti-CD4 (RM4-5), eFluor-450-
conjugated anti-CD11b (M1/70), PE-conjugated anti-CD69 (H1.2F3), PE-Cy7-conjugated anti-CD115 
(AFS98), PE-Cy7-conjugated anti-Foxp3 (FJK-16s), APC-conjugated anti-CD25 (PC61.5), V500-conjugated 
anti-B220 (RA3-6B2), PE-conjugated anti-IL-10 (JES5-16E3), PerCp-Cy5.5-conjugated anti-MHC II 
(M5/114.15.2) from eBiosciences, Alexa fluor 700-conjugated anti-CD8 (53-6.7), Brilliant Violet 421-
conjugated anti-IFN- (XMG1.2) and FITC-conjugated anti-CD107a (1D4B) from Biolegend, FITC-
conjugated anti-Ly6C (AL-21), PE-conjugated anti-Ly6G (1A8), PerCp-Cy5.5-conjugated Gr-1 (RB6-8C5), 
PE-Cy7-conjugated anti-CD11c (HL3), APC-conjugated anti-IgM (11/41) from BD Biosciences. For blood 
staining, erythrocytes were lysed using BD FACS lysing solution (BD Biosciences). For intracellular cytokine 
staining, lymphocytes were stimulated in vitro with leukocyte activation cocktail (BD Biosciences) according 
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to manufacturer’s instructions for 4 h. Surface staining was performed before permeabilization using Foxp3 
staining buffer kit (eBiosciences) and intracellular staining.  
 
Forward scatter (FSC) and side scatter (SSC) were used to gate live cells excluding RBC, debris, and cell 
aggregates in total blood cells, splenocytes, and BM. Single cell suspensions stained with fluorophore-
conjugated antibodies were acquired using an LSRII Fortessa (BD) flow cytometer and analyzed with FlowJo 
software (Miltenyi). 
 
NK cell stimulation. 
For specific NK cell stimulation, spleen cell suspensions were dispensed into 96-well 2HB Immulon plate 
previously coated with 25 g/ml of purified anti-NK1.1 antibody or 10 g/ml of anti-NKp46 antibody. Anti-
CD107a antibody was added in the presence of monensin for 4 hours.  
 
For IL-12/18 stimulation, spleen cells were incubated with 25 ng/ml IL-12 and 20 ng/ml IL-18 (R&D systems) 
for 4 hours in the presence of monensin. Cells were surface stained and intracellular IFN- was revealed. 
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Thermo Fischer Scientific, L34957) was used as a viability 
dye and the percentage of IFN--producing and CD107a-expressing NK cells was detected by Flow cytometry 
as mentioned above. 
 
Quantitative real-time PCR. 
Total ribonucleic acid (RNA) from spleen or abdominal aorta was extracted using Trizol reagent (Invitrogen). 
Quantitative real-time polymerase chain reaction (PCR) was performed on an ABI Prism 7700 Sequence 
Detection System (Thermo Fisher Scientific, Inc.) in duplicates. Cycle threshold for GAPDH was used to 
normalize gene expression of samples. Relative expression was calculated using the 2-delta-delta computed 
tomography (CT) method followed by geometric average, as recommended 32, 33. The following primer 
sequences were used: IL-10 (F: 5’ AAG TGA TGC CCC AGG CA 3’; R: 5’ TCT CAC CCA GGG AAT TCA 
AA 3’), perforin (F: 5’ ACA GTA GAG TGT CGC ATG TAC AGT TT 3’; R: 5’ GAG GGC TCT GAG CGC 
CTT TTT GAA 3’), granzyme B (F: 5’ ACT CTT GAC GCT GGG ACC TA; R: 5’ AGT GGG GCT TGA 
CTT CAT GT 3’), IFN- (F: 5’ TCA AGT GGC ATA GAT GTG GAA AGA A 3’; R: 5’ TGG CTC TGC AGG 
ATT TTC ATG 3’), TGF- (F: 5’ CGG CCG GAA ATT CCC AGC TTC T 3’; R: 5’ GTG AGA CGG GCT 
TCG GGG TCA T 3’), TNF- (F: 5’ GAT GGG GGG CTT CCA GAA CT 3’; R: 5’ CGT GGG CTA CAG 
GCT TGT CAC 3’), IL-1 (F: 5’ GAA GAG CCC ATC CTC TGT GA 3’; R: 5’ GGG TGT GCC GTC TTT 
CAT TA 3’), and IL-6 (F: 5’ AAA GAC AAA GCC AGA GTC CTT CAG AGA GAT 3’; R: 5’ GGT CTT 
GGT CCT TAG CCA CTC CTT CTG T 3’). PCR conditions were 10 min at 95°C; 42 cycles of 95°C for 15 s, 
60°C for 30s, and a final extension of 72°C for 30s. 
 
Statistical analysis. 
Values are expressed as mean +/- SEM. Differences between values were evaluated using non-parametric 
Mann-Whitney test or One-way ANOVA with Bonferroni correction to compare more than two groups. All 
these analyses were performed using GraphPad Prism version 5.0b for Mac (GraphPad Software) and values 
were considered significant at P<0.05.  
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RESULTS 
 
Genetic NK cell depletion does not alter the development of atherosclerosis. 
 
To assess the direct role of NK cells in the development of atherosclerosis, we performed BM 
transplantation experiments using either control (WT) or Ncr1iCreR26lsl-DTA BM cells to repopulate lethally 
irradiated male atherosclerosis prone-Ldlr-/- mice.  
 
 After 4 weeks of recovery, mice were put on high-fat diet (HFD) for 8, 12, or 15 weeks. Firstly, we 
confirmed NK cell depletion in spleen (Figure 1A-B), blood (Online Figure I), and BM (data not shown) of 
chimeric Ncr1iCreR26lsl-DTA Ldlr-/- mice. As expected, the frequencies of other leukocyte populations in the 
spleen (Figure 1C), blood (Online Figure I), and BM (data not shown) were not different between groups of 
chimeric mice. Data shown in Figure 1 corresponds to 8-week HFD-fed mice. Data were similar in 12- and 15-
week HFD fed-mice (data not shown). Circulating cholesterol levels and animal weights were similar between 
the two groups of mice (Online Table). Interestingly, NK cell deficiency did not alter lesion size in aortic root 
and thoracic aorta after 8 (Figure 2A-B), 12 (Figure 2C-D), or 15 weeks (Figure 2E-F) of HFD. Similarly, no 
effect was observed on atherosclerosis development in female Ldlr-/- mice reconstituted with BM of control or 
Ncr1iCreR26lsl-DTA mice and put on HFD for 8 weeks (Online Figure IIA, Figure IIB and Figure IIC). To 
determine whether plaque composition was affected by NK cell depletion, we analyzed macrophage content 
(Online Figure IID and Figure IIE), collagen content (Online Figure IIF and Figure IIG) and necrotic core (data 
not shown), but found no significant differences between groups.  
 
Furthermore, we investigated the immune-inflammatory response in chimeric Ldlr-/- mice since NK 
cells are known to produce cytokines in response to infection or inflammation 34. The expression levels of IL-
6, IL-10, IL-1, IL-12p70, TNF-, and TGF- mRNA measured in the spleen, were not different between 
control and NK cell-deficient chimeric mice (Online Figure IIIA). LPS and IFN--stimulated splenocytes from 
chimeric control or Ncr1iCreR26lsl-DTA   mice also showed no difference in inflammatory phenotype with same 
levels of IL-6, IL-10, and TNF- (Online Figure IIIB).  
 
Hyperresponsive NK cells do not promote atherosclerosis development. 
 
We next addressed the role of NK cell hyperresponsiveness in atherosclerosis by using Noé mice, in 
which a point mutation in the Ncr1 gene impairs the cell surface expression of the NKp46 receptor inducing a 
higher capacity to produce IFN- and to degranulate 26. We performed BM transplantation experiments using 
Noé or control (C57/B6J) mice to reconstitute the BM of male Ldlr-/- mice. After 8 weeks of HFD, an intact NK 
cell population (CD3-NK1.1+) was detected in Noé chimeric mice compared to controls (Figure 3 A, B, C). The 
frequencies of other leukocyte populations were also the same in spleen and blood of mice reconstituted with 
the WT or Noé BM (Figure 4S E and F). Interestingly, a higher frequency of IFN--producing NK cells was 
observed in chimera mice reconstituted with the Noé BM. However, no difference in plaque size, aortic root 
and thoracic aorta (Figure 3 D to G) or plaque composition in terms of macrophage accumulation or collagen 
content (Online Figure IVA, Figure IVB, Figure IVC and Figure IVD) was observed between groups. No 
difference in immune-inflammatory response was detected either (data not shown). This series of experiments 
was repeated twice, and similar results were found. There were no differences in plasma cholesterol levels or 
mice body weight between Noé and control chimeric mice (Online Table). 
 
These data show that NK cell hyperresponsiveness observed in Noé mice is not sufficient to affect the 
development of atherosclerosis. 
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Anti-asialo GM-1-mediated decrease in atherosclerosis is NK cell-independent. 
 
The findings with the above two experiments were unexpected, given that the latest study on the role 
of NK cell in atherosclerosis came up with the conclusion that NK cells are pro-atherogenic through their 
production of perforin and granzymes 23. Hence, we revisited the experimental model of Selathurai et al. 23, in 
which the authors used anti-asialo-GM1 antibody to deplete NK cells in Apoe-/- mice. We treated control (WT 
Ldlr-/-) or NK cell-deficient (Ncr1iCreR26lsl-DTA Ldlr-/-) chimeric mice either with anti-asialo-GM1 or control 
serum every other 5 days during the 8 weeks HFD. 
 
Initially, we examined the effectiveness of anti-asialo-GM1 treatment for depleting NK cells in 
peripheral blood. A single dose of anti-asialo-GM1 antibody was sufficient to deplete NK cells within 5 days 
by greater than 80% in WT chimeric mice (Table). NK cells are absent in Ncr1iCreR26lsl-DTA chimeric mice. 
However, anti-asialo-GM1 treatment also depleted CD8+ T and NKT populations in both control and 
Ncr1iCreR26lsl-DTA chimeric mice compared to control groups treated with control serum (Table).  
 
Similar effects in blood and spleen cells were observed in anti-asialo-GM1-treated chimeric mice after 
8 weeks of HFD. Anti-asialo-GM1 treatment led to almost 80% reduction of NK cells in control mice, between 
60% and 80% reduction in NKT cells in control and NK cell-deficient chimeric mice, respectively, and 30% 
reduction in CD8 T cells in both groups (Table).  
 
Although anti-asialo-GM1 treatment seemed to be less effective in depleting NKT and CD8+ T cell 
populations after 8 weeks HFD in the spleen, the trend towards a smaller size population persisted (Online 
Figure VA). There were no differences in the percentage of monocytes but we observed a trend of decrease in 
blood (Table) and spleen (data not shown) neutrophils. 
 
Importantly, IFN--producing CD8+ T cell population was significantly decreased by almost 50% in 
anti-asialo-GM1-treated Ncr1iCreR26lsl-DTA chimeric mice with a trend also in control anti-asialo-GM1-treated 
chimeric mice (P=0.077), while no significant differences were observed in IFN--producing CD4+ T cells 
(Online Figure VB).  
 
Lesion size decreased significantly by 42% in anti-asialo-GM1-treated control chimeric mice compared 
to mice treated with control serum (Figure 4). However, more interestingly, similar effects were observed in 
NK cell-deficient chimeric mice with 68% reduction in aortic root lesion size in anti-asialo-GM1-treated 
Ncr1iCreR26lsl-DTA chimeric mice compared to mice treated with control serum (Figure 4), despite similar plasma 
cholesterol levels (Online Table). Therefore, we concluded that reduction of atherosclerotic lesions by anti-
asialo-GM-1 treatment was NK cell-independent. 
 
NK cells exacerbate atherosclerosis development in inflammatory conditions. 
 
Finally, we addressed the role of NK cells on the development of atherosclerosis in inflammatory 
conditions in which these cells are known to be activated. To do so, we used poly(I:C), which mimics a viral 
infection. Control (WT Ldlr-/-) or NK cell-deficient (Ncr1iCreR26lsl-DTA  Ldlr-/-) chimeric mice were treated 
repeatedly with 100 g poly(I:C) twice a week, while another control group (WT Ldlr-/-  mice) was treated in 
parallel with saline over 8 weeks HFD. 
 
Interestingly, after 8 weeks of HFD, poly(I:C)-treatment of control mice significantly increased CD69 
and CD107a expression on NK cells compared to control mice that received saline, although the increase in 
frequency of IFN-producing NK cells was not significant. As expected, the percentage of NK cells 
significantly decreased by almost 50% in the spleen of poly(I:C)-treated compared to saline-treated chimeric 
mice reconstituted with WT BM (Figure 5 A). Moreover, the expression of perforin, granzyme B, and IFN- 
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mRNA was significantly enhanced in the spleen after poly(I:C) treatment, which also holds true for granzyme 
B in the aorta (Figure 5B). Interestingly, the expression of granzyme B mRNA, but not IFN-, in the spleen and 
aorta was reduced in poly(I:C) treated NK-deficient mice. This further confirm NK cell activation in response 
to poly(I:C) treatment. 
 
Although no change in aortic root plaque size was observed in poly(I:C)-treated compared to saline-
treated (WT Ldlr-/-) chimeric mice, NK cell deficiency in poly(I:C) treated chimeric mice markedly decreased 
lesion development compared with poly(I:C) treated WT controls (Figure 6). Reduction in atherosclerosis was 
associated with reduction in macrophage infiltration in (Ncr1iCreR26lsl-DTA  Ldlr-/-) poly(I:C)-treated mice 
compared to poly(I:C)-treated control mice (Online Figure VIA). No change in collagen content was detected 
(Online Figure VIB). No differences in body weight or serum cholesterol levels were observed between the 3 
groups of mice (Online Table). Hence, NK cells might be proatherogenic when activated in a systemic 
inflammatory context. 
 
NK cells are scarcely detected in human and mouse atherosclerotic lesions. 
 
To specifically track NK cell homing to atherosclerotic lesions in hypercholesterolemic mice, we 
reconstituted lethally irradiated Ldlr-/- mice with BM from Ncr-1gfp/gfp mice. After 8 weeks of HFD, staining of 
atherosclerotic lesions with anti-GFP-antibody showed very low number of NK cells, 1 to 2 cells per lesion 
examined (Figure 7 A). In contrast, NK cells were abundant in the spleen. 
 
In human, we also found very few NK cells in atherosclerotic plaques. Only one or two cells were 
detected in the plaques of uncomplicated atherosclerosis, while none were observed in advanced plaque lesions 
(Figure 7 B). Specificity of the anti-human NKp46 antibody was tested in human spleen samples. 
 
 
 
DISCUSSION 
 
Using two state-of-the-art genetic approaches, our study provides strong evidence that, in contrast to 
most previous studies, NK cells have no role in atherosclerosis development, unless a systemic inflammation 
is induced. Transfer of the BM of selectively depleted (Ncr1iCreR26lsl-DTA) or hyper-responsive (Noé) mice into 
lethally irradiated Ldlr-/- mice had no effect on plaque size (aortic root and thoracic aorta) and composition, or 
immune-inflammatory response, as compared with control mice. However, treating NK cell-deficient chimeric 
mice with poly(I:C), in an attempt to mimic viral infection, significantly reduced lesion size, which suggests 
that NK cells might be proatherogenic only when activated by virus infection or inflammatory cytokines or in 
the context of tumor growth.  
 
Earlier studies on the role of this innate immune cell population in atherosclerosis led to conflicting 
results. The very first studies to examine the role of NK cells in atherosclerosis used the Beige mutant mice. 
Accelerated atherosclerosis was observed in beige Ldlr-/- mice and NK cells were accredited to be anti-
atherogenic 12. However, an alternative NK-cell independent hypothesis is most likely since the beige mutation 
which leads to functional changes in lysosome trafficking may involve other cells such as lesion macrophages 
or SMCs leading to increased foam cell formation or apoptosis 35, 10. In contrast to these studies, Ldlr-/- mice 
repopulated with Ly49A transgenic mice BM and which present a NK cell deficiency exhibited reduced 
atherosclerosis 7. However, the expression of the inhibitory receptor Ly49A, which is regulated by granzyme 
A promoter in this model, is induced not only in NK cells, but also in subsets of CD4+ and CD8+ T cells 16. 
Hence, this expression on T cells could be responsible for the decrease in lesion size in Ly49A transgenic BM 
recipients. Lately, experiments in Apoe-/- mice fed a HFD treated with anti-asialo-GM1 antibody to deplete NK 
cells attenuated atherosclerosis. In addition, adoptive transfer of ex vivo activated NK cells increased lesion size 
in lymphocyte deficient Apoe-/- mice, an effect that was prevented by transferring perforin or granzyme-
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deficient NK cells, with suggests that NK cells augment atherosclerosis via cytotoxic dependent mechanisms 
23. However, the expression of asialo-GM1 is not strictly confined to NK cells among hematopoietic cells and 
is detected in subpopulations of NKT, CD8 T, and T cells 36, 37 and in some activated forms of CD4+ T cells, 
macrophages, eosinophils, and basophils under certain experimental conditions 38, 39, 40. Our data suggest that 
the discrepancy observed in former studies was most likely due to effects on other cell populations targeted in 
addition to NK cells. Indeed, our study clearly demonstrates that NK cells have no role in atherosclerosis 
development.  
 
NKp46 is also expressed in ILC1 and a subset of ILC3 (NKp46+ ILC3s). These cells are also deleted 
in the Ncr1iCreR26RDTA mice 25. In our experimental protocol, recipient mice were irradiated before BM 
transplantation. Both NK cells and ILC1s are sensitive to irradiation and should thus originate from donor BM. 
Regarding the ILC3 population, NKp46- ILC3 have been shown to be resistant to irradiation 41, 42, but we have 
no information about the radioresistance of NKp46+ ILC3. Therefore, in our model of BM transplantation of 
Ncr1iCreR26RDTA BM into irradiated Ldlr-/- mice, not only NK cells but also ILC1s and potentially NKp46+ 
ILC3s should have been depleted, while other lymphocytes and myeloid cells were unaffected suggesting that 
these other ILCs subset do not play a major role in atherosclerosis either. 
 
Moreover, we questioned the specificity of using anti-asialo GM1 treatment to target NK cells in the 
context of atherosclerosis. We clearly demonstrated its effect was NK cell-independent as atherosclerosis was 
reduced by anti-asialo-GM1 treatment to the same extent in control and NK-deficient mice. We observed that 
the anti-asialo-GM1 treatment not only depleted NK cells, but also strongly reduced NKT and CD8+ T cell 
population after 8 weeks of HFD. Among CD8+ T cells, the IFN--producing CD8 T cells was also reduced. 
This is consistent with a previous study showing that the asialo-GM1+ CD8 population are high IFN--
producing cells in response to stimulus 36. These activated CD8+ T cells which are targeted by anti-asialo-GM1 
antibodies might thus be involved in the phenotype observed in atherosclerosis. This is consistent with the fact 
that CD8+ T cell activation has been shown to exacerbate atherosclerosis 43. Regarding the NKT cell population, 
although previous studies indicate that NK cell depletion with antibody against asialo-GM1 does not always 
drastically affect the size or function of NKT cell population 44, NKT cell population was significantly 
decreased in hypercholesterolemic mice treated with anti-asialo-GM1 antibody. NKT cells are considered pro-
atherogenic 45. Their depletion could thus also contribute to the protective phenotype in anti-asialo-GM1-treated 
mice.  
 
We used two models in which NK cells functions are increased: the Noé model in which NK cells are 
known to be intrinsically hyperresponsive and the poly(I:C) model in which NK cells are activated due to an 
inflammatory environment. 
 
Using the Noé mice, we showed that NK cell hyperresponsiveness in sterile conditions does not affect 
the atherosclerotic process, although hypercholesterolemia modestly increased IFN--producing NK cell 
population. In contrast, a non-redundant role of NK cells was revealed in an inflammatory context induced by 
chronic poly(I:C) injection. Along this line, previous studies reported an aggravation of atherosclerosis in 
hypercholesterolemic mice infected with mouse Cytomegalovirus (MCMV) 46. NK cells are one of the first 
innate immune cells to respond to and contain the MCMV infection through their direct perforin mediated 
cytotoxicity function and IFN- release 47. In our study, the viral mimic poly(I:C) significantly augmented NK 
cell activation marker CD69 as well as CD107a degranulation marker. CD107a is a lysosomal associated 
membrane protein lining the membrane of cytotoxic granules 48. Its expression is correlated with degranulation 
and target cell lysis 49. In addition, in our experiments, we noticed an upregulation of the mRNA of perforin, 
granzyme B, and IFN- in the spleens of poly(I:C)-treated control mice, which highlights the marked activation 
of NK cells in response to poly(I:C).  Interestingly, only the expression of granzyme B was significantly 
decreased in both spleen and aorta of poly(I:C) treated NK-deficient mice, which points out to a role of NK 
cytolysis in the proatherogenic effects of NK cells, in agreement with previous studies by Selathurai et al.23 In 
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control mice, we observed no effect of poly(I:C) on atherosclerosis in the aortic root. The discrepancy observed 
could be attributed to the multiple effects of poly(I:C) in atherosclerosis context. Zimmer et al. demonstrated 
that intravenous administration of poly(I:C) induced endothelial dysfunction and increased atherosclerotic 
lesion development 50. In contrast, Monaco’s group described poly(I:C)-mediated atheroprotection. 
Intraperitoneal administration of poly(I:C) attenuated neointima formation and reduced injury induced media 
damage 51. Further studies are required to fully elucidate how poly(I:C) influence atherosclerosis. Nonetheless, 
this series of experiments clearly establish that even though resting NK cells have no effects on atherosclerosis, 
NK cells might exacerbate atherosclerosis in case of activation by an inflammatory context like viral infections. 
The ability of activated NK cells to influence other immune cells in the atherosclerotic process should be 
considered. In immune competent mice, NK cell-derived IFN- promotes CD4+ TH1 priming 52. It is well 
established that IFN--producing TH1 subset is a major proatherogenic subset of the adaptive immune system 
and may activate pro-atherogenic properties of both vascular and immune cells 53. Moreover, perforin and 
granzymes, which are highly augmented after poly(I:C) treatment, lead to target cell apoptosis and can 
accelerate atherosclerosis by increasing necrosis 23.  
 
In conclusion, our findings indicate that NK cells have no role in atherosclerosis development in 
hypercholesterolemic mice, unless a super-imposed inflammatory status mimicking viral infection is induced. 
Further studies are needed for detailed characterization of the mechanisms whereby NK cells’ response to viral 
infection would influence the atherosclerotic process.  
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FIGURE LEGENDS 
 
Figure 1. (A and B) Efficiency of NK cell (CD3-NK1.1+NKp46+) depletion in spleen (gated on total viable 
splenocytes) of male Ldlr-/-mice reconstituted with the BM of NK cell-deficient (Ncr1iCreR26lsl-DTA  Ldlr-
/-) (n=10) compared to control mice (WT  Ldlr-/-) (n=8) after 8 weeks of high fat diet (HFD). (C) 
Representative quantitative analysis of the percentage of myeloid (neutrophils, monocytes (classical and 
non-classical), and dendritic cells) and lymphoid (CD4+, CD8+, and NKT cells) populations in the spleen 
of control and NK cell-deficient chimeric mice assessed by flow cytometry, after 8 weeks of HFD. ***p < 
0.001 
 
Figure 2. Representative photomicrographs of Oil red O-staining and quantification of lesion size in aortic 
sinus (A) or thoracic aorta (B) of male controls (WT  Ldlr-/-) (n=8) and NK cell-deficient (Ncr1iCreR26lsl-
DTA  Ldlr-/-) (n=10) mice after 8 weeks (A-B), 12 weeks (n=7 – 6, respectively) (C, D), or 15 weeks (n=5 
– 3, respectively) HFD (E, F). 
 
Figure 3. Representative flow cytometry plots (A) and quantitative (B) analysis of the percentage of (B) 
NK cells in the splenocytes of controls (WT  Ldlr-/-) and (Noé  Ldlr-/-) 
chimeric mice gated on CD3-NK1.1+ cells and (C) IFN-γ-producing NK cells gated on CD3-NK1.1+ cells. 
Representative photomicrographs of Oil red O-stained atherosclerotic lesions in the aortic sinus (D) and 
thoracic aorta (F) of male controls (n=8) and Noé chimeric mice (n=7), along with their corresponding 
quantifications (E and G, respectively) after 8 weeks HFD. **p < 0.01 
 
Figure 4. Representative photomicrographs of Oil Red O-staining (A and B) and quantification of lesion 
size in left aortic sinus (C) after 8 weeks of HFD of male controls (A) and NK cell-deficient mice (B) treated 
with either α-Asialo-GM1 or control serum (n=10 per group). *p < 0.05, ***p < 0.001 
 
Figure 5. (A) Representative quantitative analysis of flow cytometry-based staining of NK cells (gated on 
CD3-NK1.1+), CD69+ NK cells (gated on CD3-NK1.1+), IFN-+ NK cells (gated on CD3-NK1.1+), and 
CD107a+ NK cells (gated on CD3-NK1.1+) in the three groups of mice: controls (WT  Ldlr-/-) treated with 
saline (n=6) or poly(I:C) (n=11) and NK cell-deficient (Ncr1iCreR26lsl-DTA   Ldlr-/-) mice treated with 
poly(I:C) (n=13). (B) Quantification of perforin, granzyme B, and IFN- mRNA expression in the spleens 
and abdominal aorta of the 3 groups of chimeric mice. *p < 0.05, **p < 0.01, ***p < 0.001 
 
Figure 6. Representative photomicrographs of Oil red O-staining (A) and quantification of lesion size in 
left aortic sinus (B) after 8 weeks of HFD in the three groups. **p < 0.01 
 
Figure 7. (A) Photomicrographs of NK cells (anti-GFP+) detected in spleen and aortic sinus of Ncr-1gfp/gfp 
 Ldlr-/- mice (n=3) at 8 weeks HFD, the dashed line marks the intima; L: lumen; A: adventitia. (B) 
Immunohistochemistry in human atherosclerotic plaques (n=17). Few NKp46+ NK cells (brown) are 
detected in early fatty streak lesions (n=5), and none in advanced carotid artery plaques (n=12). 
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NOVELTY AND SIGNIFICANCE  
 
What Is Known? 
 
 Adaptive immunity contributes to atherosclerosis.  
 
 The role of Natural Killer (NK) cells in atherosclerosis has been investigated in murine models in the 
past, but the results have been mixed. 
 
 The previous mouse models are limited by a lack of selectivity with regard to deletion of NK cells. 
 
 
What New Information Does This Article Contribute? 
 
 Specific NK deletion or hyperesponsiveness does not affect atherosclerosis development in 
hypercholesterolemic mice. 
 
 The absence of NK cells under simulated viral infection reduces atherosclerosis. 
 
In general, previous studies suggested that NK cells play a proatherogenic role, however one recent study 
reported that NK cells are atheroprotective. These studies used loss of NK cell function in several mouse 
models, including Beige mutant mice, Ly49A transgenic mice, and antibody-mediated depletion (anti-
asialo-GM1 antibody) in vivo approach. These models are limited by a lack of selectivity with regard to 
deletion of NK cells; they may involve loss of function for other immune cells, including neutrophils, 
macrophages or smooth muscles cells. In this study, we used two novel mouse models to investigate the 
role of NK cells in atherosclerosis: 1) Ncr1iCreR26IsI-DTA model, where NK cells are specifically deleted; 2) 
the Noé mice in which NK cells are hyperresponsive. Our study provides novel evidence for the lack of a 
role for NK cells in atherosclerotic development in bone marrow transplantation studies in Ldlr-/- mice. 
However, data using the viral mimic Poly(I:C) demonstrates a significant reduction of plaque size in NK-
cell deficient chimeric mice, supporting a proatherogenic role for NK cells when activated by inflammatory 
conditions. 
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Table: Quantitative analysis of the percentage of blood cells 5 days after starting treatment with anti-Asialo-GM1 and after 8 weeks HFD in 
controls (WT  Ldlr-/-) and NK cell-deficient (Ncr1iCreR26lsl-DTA  Ldlr-/-) mice treated with either anti-Asialo-GM1 or control serum. 
(*p < 0.05; **p < 0.01; ***p < 0.001). Monocyte and neutrophil percentages were not assessed at 5 days post injection. N.D: not determined 
 
 
                       5-day HFD                                                                        8-week HFD 
 
 
 
WT --> Ldlr-/- Ncr1iCreR26Rlsl−DTA 
-->  Ldlr-/- 
WT --> Ldlr-/- Ncr1iCreR26Rlsl−DTA 
-->   Ldlr-/- 
control Ab a-asialo control Ab a-asialo control Ab a-asialo control Ab a-asialo 
% NK 6.5±0.7 1.1±0.3*** N.D N.D 3.6±0.5 0.8±0.2*** N.D N.D 
% NKT 0.7±0.1 0.3±0.05* 0.80±0.1 0.32±0.1** 0.4±0.07 0.2±0.04** 0.4±0.04 0.08±0.03*** 
% CD4 11.6±1.6 11.3±1.3 12±1.4 13.4±1.4 9.5±0.6 8.9±0.9 7.8±0.6 7.9±0.5 
% CD8 6.1±0.4 3.4±0.2*** 7.1±0.6 2.3±0.3*** 4.5±0.3 3.1±0.3* 3.8±0.2 2.7±0.2* 
% Neutrophils - - - - 16.3±4 12.6±2 18.8±3 14.1±1.7 
% Monocytes - - - - 8.8±0.8 8.9±0.8 8.4±0.6 9.9±0.8 
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